License allows Transomic Technologies to develop and commercialize products using CRISPR/Cas9. Dublin, Ireland and Huntsville, AL, USA, August 3, 2023: ERS Genomics Limited (‘ERS’) is…
Someone’s famous uncle once said, “With great power comes great responsibility.” Genome editing is an incredibly powerful technique with huge promise and potential for medicine,…
SynBioBeta 2023 With ERS’ Paul Carter – Sr. Director Business Development & Licensing, North America https://ersgenomics.com/wp-content/uploads/2023/06/Paul-Carter-SynBioBeta-audiogram.mp4 SynBioBeta 2023: Time to scale The recent SynBioBeta conference…
ERS Genomics & abm enter into CRISPR/Cas9 Licensing Agreement This License allows abm to develop and commercialize products using CRISPR/Cas9 technology. Dublin, Ireland and Vancouver,…
“Although CVC and Broad’s CRISPR/Cas9 gene editing patents currently coexist in the US, pending federal circuit appeal, the picture is clearer in the EPO opposition…
Find out what role #CRISPR has to play in the new bio-industrial revolution in our latest article on #synbio and CRISPR’d #chemicals @GENbio https://www.genengnews.com/topics/bioprocessing/crispr-made-greener-products-and-processes-in-industrial-biotechnology/